about
Optimizing drugs to reach treatment targets for children and adolescents living with HIVHaematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trialResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisSwitching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in ThailandPediatric HIV — A Neglected Disease?Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in ThailandHematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in ThailandInfluence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyLong-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study.Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settingsNo relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in ThailandEstimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution modelThe interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers.Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmissionAn analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenNucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudinePrevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant womenFive-year trends in antiretroviral usage and drug costs in HIV-infected children in ThailandAnalysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.The prevention of mother-to-child transmission of HIV: are we translating scientific success into programmatic failure?Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
P50
Q26774255-AB931562-7D8C-407E-8531-8FFD88DD5194Q28469195-387C281F-3CEC-4C67-8F9D-A9873FAF4838Q28478121-8DFCE519-8386-4D65-A9F8-156DF67E44C9Q28535141-5515AE81-9CDD-4BD9-A6AA-5BC0743CA224Q29013261-2AC0ED66-7B4E-417F-873D-1EF829A6E9F4Q33714594-866398A5-6DA0-430A-A9AB-78526766C6DBQ33798282-DAC7C350-AE4A-4B95-AE1E-B90B7B865686Q33827080-37E7BEA9-978C-4F61-88DA-BE805AF838E7Q33915385-41A4AD37-B822-4F55-9085-0B30FAAECBF7Q34315335-541C9D70-C552-49D2-BFDB-6CA32EF66E42Q34332659-EF0CA0F2-3BE3-4D08-A2F6-978A3FCFC05FQ34364620-9F310794-7184-47D2-B596-B26F839D290BQ34385049-F3F420C0-D1F0-4892-BECF-3D8035E8A5C7Q34677780-CD9AA931-F203-4886-9AC1-28F5FA80F2E3Q34710705-6C0A15EE-35B5-47E4-8894-37BC8EAA6DDCQ34758192-68EB3639-76F7-46F1-872C-34E3EC36D5C9Q35019846-4EFB1AC0-5D77-4F71-AE35-09C59A683EFAQ35036360-3930B84E-E49D-4925-AB0F-EE4E3989B1CEQ35102254-4CAEE3A1-985F-4439-8BFA-3C67EB959AD6Q35121725-B48A72B7-4456-4B28-9888-347DB62445F9Q35143626-D73AAEE8-7A95-467C-A8F9-E46B6FF9D9CBQ35612521-517B83F0-7AA7-4AE3-A77A-F06C64B8711AQ35625548-C410C78A-F93C-4107-AC4C-606F22DE712CQ35744396-CEA61242-ECCE-432B-A849-3336BAEA3603Q35958603-86C04869-22FA-4893-8B3E-228321135F85Q36094847-91F7671C-F389-474D-95C9-FE6557756441Q36186007-9D3AAE9B-A81E-407A-9EEE-D3013E19771FQ36542643-4D3A03ED-0267-4BE7-83CC-AAFDB1CED5ECQ36625456-3EE5CBF0-63FE-48BB-84BB-CE5158F854E1Q36683440-6F88AB76-52A3-483E-B351-7133979552F2Q36852626-9E76D980-483D-4F19-A236-E7185099488FQ36999993-7EDD590B-BF52-4055-8490-1D19F31FD06BQ37098285-B4C71DB3-7DE4-44CD-A22B-62054AC27B1DQ37412223-82327A4C-C1FE-4288-A217-7C1C110A3FCDQ37417511-F91088C5-9DAA-407C-9FB6-7645AAF85A5EQ37447560-658642F8-A594-4BAF-A950-C838783CC3E7Q38854786-315BD5DA-18A4-43F4-894A-FD4928D1958FQ38862428-F020B454-911F-4955-982E-969B57D108D5Q38874266-7A5DE502-C2D4-4ED4-9BC2-DF7D2A8A11D0Q39231462-F9DF4602-AD0A-455C-A70E-A3E8DA96FD69
P50
description
onderzoeker
@nl
name
Marc Lallemant
@ast
Marc Lallemant
@en
Marc Lallemant
@es
Marc Lallemant
@sl
type
label
Marc Lallemant
@ast
Marc Lallemant
@en
Marc Lallemant
@es
Marc Lallemant
@sl
prefLabel
Marc Lallemant
@ast
Marc Lallemant
@en
Marc Lallemant
@es
Marc Lallemant
@sl